The proliferation program included MKI67, which is a typical biomarker used in the clinic to indicate the proliferating properties of SCLC, and TOP2A (topoisomerase II), which is the target of etoposide that is most frequently used for SCLC treatment in combination with platinum (Supplementary Fig. S3c). This evidence concerns the gene TOP2A and small cell lung carcinoma.